Apimeds Pharmaceuticals US, Inc. (APUS) share price
Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS) last traded at $2.71, down 0.92% on the day (quote 2026-11-06 20:58 UTC), with a market cap of $0.00B and a 52-week range of $1.51 to $59.7.
| Exchange | NYSE American |
|---|---|
| Currency | USD |
| Last price | $2.71 |
| 1-day move | -0.92% |
| 52-week range | $1.51 - $59.7 |
| Market cap | $0.00B |
| From 52-week high | -95.50% |
| Volume vs average | 0.0x |
| Falling Shares risk score | 24/100 (MODERATE) |
| Country | United States |
Frequently asked questions
Why is Apimeds Pharmaceuticals US, Inc. falling today?
Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS) is down 0.92% at its latest quote and trades 95.5% below its 52-week high. A price fall alone does not identify a cause: Falling Shares Intelligence links a move to a filing, order or news item only when a source supports it.
What is the Apimeds Pharmaceuticals US, Inc. share price today?
Apimeds Pharmaceuticals US, Inc. (NYSE American:APUS) last traded at $2.71, a -0.92% move on the day as of 2026-11-06 20:58 UTC. Market data comes from public feeds and may be delayed; it is not investment advice.
What is the 52-week range of Apimeds Pharmaceuticals US, Inc.?
Apimeds Pharmaceuticals US, Inc.'s 52-week low is $1.51 and its 52-week high is $59.7; the shares trade 95.5% below the high.
What is the market cap of Apimeds Pharmaceuticals US, Inc.?
Apimeds Pharmaceuticals US, Inc. has a market capitalisation of about $0.00B at the latest price.
What are the risks of investing in Apimeds Pharmaceuticals US, Inc.?
Falling Shares Intelligence rates Apimeds Pharmaceuticals US, Inc. 24/100 (MODERATE) on price stress, volume and disclosure signals. Risk scores are analytical indicators, not allegations or investment advice. Review exchange filings and the company's own disclosures before any decision.
Data is compiled from public exchange feeds and may be delayed. Not investment advice.
Wung Thomas, Editor-in-Chief: wungthomas@fallingshares.com. General enquiries and corrections: info@fallingshares.com